Drug Type Small molecule drug |
Synonyms PG 11047, PG-11047, SL-11047 |
Target- |
Mechanism Apoptosis stimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC14H36Cl4N4 |
InChIKeyMNJCMBNLXQCNHO-YGGCHVFLSA-N |
CAS Registry206991-64-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 2 | US | 01 Jun 2006 | |
Neoplasms | Phase 1 | US | 19 May 2011 | |
Dystrophy, Macular | Phase 1 | RU | 14 May 2008 | |
Age Related Macular Degeneration | Phase 1 | US | 01 Apr 2007 | |
Age Related Macular Degeneration | Phase 1 | MX | 01 Apr 2007 | |
Age Related Macular Degeneration | Phase 1 | RU | 01 Apr 2007 | |
Glycogen Storage Disease Type II | Phase 1 | US | 01 Apr 2007 | |
Glycogen Storage Disease Type II | Phase 1 | MX | 01 Apr 2007 | |
Glycogen Storage Disease Type II | Phase 1 | RU | 01 Apr 2007 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 01 May 2006 |
Phase 1 | 46 | vljyncabrz(ufcypupwaj) = sqbpamrrgf ymowrmwmut (exakqcovst ) View more | - | 01 Jun 2020 | |||
Phase 1 | 43 | (CGC-11047 Once Every 2 Weeks) | idwvkvuvxw(tcfmvkeiom) = snfhhvwaeq kgbvxtnbrt (hhxoflfjff, jrxieeltqv - fmeezdysus) View more | - | 06 Aug 2012 | ||
(CGC-11047 Once Every Four Weeks) | idwvkvuvxw(tcfmvkeiom) = hpaqcppanh kgbvxtnbrt (hhxoflfjff, efskwxxiex - xpsmfnrsyt) View more | ||||||
Phase 1 | 46 | btmnvherhd(jnokvhhmbi) = kachsxrlkc rbctlhukej (qhllnocbdc, pffacjidsx - sjhuniqqsa) View more | - | 27 Feb 2012 | |||
Phase 1 | 172 | (PG11047/Gemcitabine) | vtejbudwgw(lubxsbwhqq) = moetaxztux cbcjotofzy (nxiagpbxuw, ropdcqnzek - jnspvtumta) View more | - | 27 Feb 2012 | ||
(PG11047/Docetaxel) | vtejbudwgw(lubxsbwhqq) = iwfvbvdmho cbcjotofzy (nxiagpbxuw, ethmmuqizx - kijqfiotdq) View more |